Fulgent Genetics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Fulgent Genetics, Inc. on May 30, 2019, in El Monte, California. The filing was submitted on June 3, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 5, 2019), 18,287,400 shares were outstanding. A quorum of 89% (16,295,709 shares) was present for the meeting. Two proposals were voted upon:
- Proposal 1 (Election of Directors): Four directors were elected to one-year terms. All nominees received significant support with minimal votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the final composition of the Board of Directors following the election of Ming Hsieh, John Bolger, James J. Mulay, and Yun Yen.
- Confirm the engagement of Deloitte & Touche LLP for the 2019 fiscal year audit.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.